A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses

N.D. Oreshkova; Sebenzile K. Myeni; Niraj Mishra; Irina C. Albulescu; Tim J. Dalebout; Eric J. Snijder; Peter J. Bredenbeek; Kai Dallmeier; Marjolein  Kikkert

doi:10.3390/vaccines9121492

A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses

N.D. Oreshkova, Sebenzile K. Myeni, Niraj Mishra, Irina C. Albulescu, Tim J. Dalebout, Eric J. Snijder, Peter J. Bredenbeek, Kai Dallmeier, Marjolein Kikkert

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Abstract

The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy record in humans, and therefore, it is a very attractive platform for the development of novel chimeric vaccines against various pathogens. In the present study, we generated a YF17D-based replicon vaccine platform by replacing the prM and E surface proteins of YF17D with antigenic subdomains from the spike (S) proteins of three different betacoronaviruses: MERS-CoV, SARS-CoV and MHV. The prM and E proteins were provided in trans for the packaging of these RNA replicons into single-round infectious particles capable of expressing coronavirus antigens in infected cells. YF17D replicon particles expressing the S1 regions of the MERS-CoV and SARS-CoV spike proteins were immunogenic in mice and elicited (neutralizing) antibody responses against both the YF17D vector and the coronavirus inserts. Thus, YF17D replicon-based vaccines, and their potential DNA- or mRNA-based derivatives, may constitute a promising and particularly safe vaccine platform for current and future emerging coronaviruses. View Full-Text

Original language	English
Article number	1492
Journal	Vaccines
Volume	9
Issue number	12
DOIs	https://doi.org/10.3390/vaccines9121492
Publication status	Published - 16 Dec 2021
Externally published	Yes

Keywords

Coronavirus
MERS-CoV
Neutralizing antibodies
RBD
S1
SARS-CoV
SARS-CoV-2
Spike protein
Vaccine platform
YF17D
YFV-17D

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vaccines9121492Licence: CC BY

Cite this

@article{882a012cbb6f49c091d65367e394bfb6,

title = "A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses",

abstract = " The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy record in humans, and therefore, it is a very attractive platform for the development of novel chimeric vaccines against various pathogens. In the present study, we generated a YF17D-based replicon vaccine platform by replacing the prM and E surface proteins of YF17D with antigenic subdomains from the spike (S) proteins of three different betacoronaviruses: MERS-CoV, SARS-CoV and MHV. The prM and E proteins were provided in trans for the packaging of these RNA replicons into single-round infectious particles capable of expressing coronavirus antigens in infected cells. YF17D replicon particles expressing the S1 regions of the MERS-CoV and SARS-CoV spike proteins were immunogenic in mice and elicited (neutralizing) antibody responses against both the YF17D vector and the coronavirus inserts. Thus, YF17D replicon-based vaccines, and their potential DNA- or mRNA-based derivatives, may constitute a promising and particularly safe vaccine platform for current and future emerging coronaviruses. View Full-Text ",

keywords = "Coronavirus, MERS-CoV, Neutralizing antibodies, RBD, S1, SARS-CoV, SARS-CoV-2, Spike protein, Vaccine platform, YF17D, YFV-17D",

author = "N.D. Oreshkova and Myeni, {Sebenzile K.} and Niraj Mishra and Albulescu, {Irina C.} and Dalebout, {Tim J.} and Snijder, {Eric J.} and Bredenbeek, {Peter J.} and Kai Dallmeier and Marjolein Kikkert",

year = "2021",

month = dec,

day = "16",

doi = "10.3390/vaccines9121492",

language = "English",

volume = "9",

journal = "Vaccines",

issn = "2076-393X",

publisher = "MDPI",

number = "12",

}

TY - JOUR

T1 - A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses

AU - Oreshkova, N.D.

AU - Myeni, Sebenzile K.

AU - Mishra, Niraj

AU - Albulescu, Irina C.

AU - Dalebout, Tim J.

AU - Snijder, Eric J.

AU - Bredenbeek, Peter J.

AU - Dallmeier, Kai

AU - Kikkert, Marjolein

PY - 2021/12/16

Y1 - 2021/12/16

N2 - The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy record in humans, and therefore, it is a very attractive platform for the development of novel chimeric vaccines against various pathogens. In the present study, we generated a YF17D-based replicon vaccine platform by replacing the prM and E surface proteins of YF17D with antigenic subdomains from the spike (S) proteins of three different betacoronaviruses: MERS-CoV, SARS-CoV and MHV. The prM and E proteins were provided in trans for the packaging of these RNA replicons into single-round infectious particles capable of expressing coronavirus antigens in infected cells. YF17D replicon particles expressing the S1 regions of the MERS-CoV and SARS-CoV spike proteins were immunogenic in mice and elicited (neutralizing) antibody responses against both the YF17D vector and the coronavirus inserts. Thus, YF17D replicon-based vaccines, and their potential DNA- or mRNA-based derivatives, may constitute a promising and particularly safe vaccine platform for current and future emerging coronaviruses. View Full-Text

AB - The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy record in humans, and therefore, it is a very attractive platform for the development of novel chimeric vaccines against various pathogens. In the present study, we generated a YF17D-based replicon vaccine platform by replacing the prM and E surface proteins of YF17D with antigenic subdomains from the spike (S) proteins of three different betacoronaviruses: MERS-CoV, SARS-CoV and MHV. The prM and E proteins were provided in trans for the packaging of these RNA replicons into single-round infectious particles capable of expressing coronavirus antigens in infected cells. YF17D replicon particles expressing the S1 regions of the MERS-CoV and SARS-CoV spike proteins were immunogenic in mice and elicited (neutralizing) antibody responses against both the YF17D vector and the coronavirus inserts. Thus, YF17D replicon-based vaccines, and their potential DNA- or mRNA-based derivatives, may constitute a promising and particularly safe vaccine platform for current and future emerging coronaviruses. View Full-Text

KW - Coronavirus

KW - MERS-CoV

KW - Neutralizing antibodies

KW - RBD

KW - S1

KW - SARS-CoV

KW - SARS-CoV-2

KW - Spike protein

KW - Vaccine platform

KW - YF17D

KW - YFV-17D

U2 - 10.3390/vaccines9121492

DO - 10.3390/vaccines9121492

M3 - Article

SN - 2076-393X

VL - 9

JO - Vaccines

JF - Vaccines

IS - 12

M1 - 1492

ER -

A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this